

UNIVERSITI TEKNOLOGI MARA

**GENETIC RISKS OF CHILDHOOD
LYMPHOBLASTIC LEUKAEMIA
AND THE INTERPATIENT
VARIATION OF METHOTREXATE
RESPONSES AMONG PATIENTS**

RIZAL HUSAINI BIN RAZALI

PhD

July 2021

AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the results of my own work, unless otherwise indicated or acknowledged as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student : Rizal Husaini bin Razali

Student I.D. No. : 2016898038

Programme : Doctor of Philosophy (Pharmacogenomics) – PH950

Faculty : Pharmacy

Thesis Title : Genetic Risks of Childhood Lymphoblastic
Leukaemia and The Interpatient Variation of
Methotrexate Responses Among Patients

Signature of Student :

Date : July 2021

ABSTRACT

Acute lymphoblastic leukaemia is the most prevalent cancer in children under 14 years of age in Malaysia, with an incidence rate of approximately 35 per one million children. Several potential environmental and lifestyle factors associated with the risk of childhood leukaemia have been investigated, such as infections, pesticides, traffic air pollution, industrial pollutant, diet, parental occupation and smoking habit. The study aimed to determine relationships between two SNPs; rs10821936 (*ARID5B*) and rs25487 (*XRCCI*), and risk associated in childhood ALL, as well as four SNPs; rs717620 (*ABCC2*), rs4948496 (*ARID5B*), rs1801133 (*MTHFR*) and rs4149056 (*SLCO1B1*), with the serum levels and toxicity of MTX. The study also sought to investigate the metabolic alterations associated with MTX and to determine the potential metabolic markers and pathway for drug responses. Genomic DNA was isolated from blood, and the polymerase chain reaction analysis was performed for the genotyping study. The variants were then annotated and analysed utilising Variant Effect Predictor (VEP), Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyping version 2 (PolyPhen-2). In addition, the Agilent 1200 Infinity HPLC system coupled with the Agilent 6460 triple-quadrupole (QQQ) and Agilent 6520 Accurate-Mass (Q-TOF) mass spectrometers were employed to measure serum concentrations of MTX and to identify the potential metabolic markers, respectively. Eighty-one per cent of the patients have genotypes CC and CT of rs10821936 (*ARID5B*) were associated with 2.5 – 2.1 increase in the risk of developing ALL. The rs717620 *ABCC2* genotype was significantly associated with MTX serum levels at 48 hours post-treatment ($p = 0.017$, Kruskal-Wallis Test). Patients with CT and TT of rs717620 (*ABCC2*) and TC and CC of rs4948496 (*ARID5B*) were significantly associated with grade I – IV leukopenia (Fisher Exact Test; $p = 0.03$ and 0.02 , respectively). The metabolomics study found that thirteen metabolites significantly discriminated the pre- and post-MTX group. Out of the thirteen metabolites identified, the four metabolites with VIP scores of more than 1 were xanthine, alpha-linolenic acid, (9Z)-hexadecenoic acid and cholic acid. The findings revealed that xanthine was the most significant metabolic marker in childhood ALL with an AUC value of 0.88 (95%, CI = 0.84 – 0.92). Our results demonstrate that by pre-screening of ALL patients would identify whose patients at risk and therefore help a paediatric oncologist to personalize chemotherapy drugs for precision health.

ACKNOWLEDGEMENT

First and foremost, I would like to thank and praise Allah the Almighty for allowing me to conduct and successfully complete PhD research.

My gratitude and thanks go to my supervisor, Professor Dr Teh Lay Kek for her immeasurable and generous support throughout the research process. I would like to thank my co-supervisors, YBhg. Professor Dato' Dr Mohd Zaki bin Salleh, YBhg. Datuk Dr Hishamshah bin Mohd Ibrahim and Dr Teh Kok Hoi for all their boundless effort in assisting me to complete this research and making this research a success. The research has brought a whole lot of new experience and has provided me with such special tools and skills to be applied in my future. I was truly honoured to have the opportunity to work with these professional and wonderful peoples.

I would like to express my gratitude to the Ministry of Health Malaysia for granting me the Hadiyah Latihan Persekutuan (HLP) scholarship. Special thanks to my colleagues and friends for helping me with this project. Finally, this thesis is dedicated to my parents, Razali bin Ismail and Sharifah binti Mamat for the vision and determination to educate me. This piece of victory also dedicated to my wife, Nurhidayah binti Arshad and my daughter, Siti Afiqah binti Rizal Husaini.

Alhamdulillah.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xii
LIST OF FIGURES	xv
LIST OF SYMBOLS	
xix	
LIST OF ABBREVIATIONS	xx
CHAPTER ONE: INTRODUCTION	1
1.1 Background of Study	1
1.2 Problem Statement	3
1.3 Objectives of the Study	6
CHAPTER TWO: LITERATURE REVIEW	8
2.1 Childhood Acute Lymphoblastic Leukaemia (ALL)	8
2.1.1 Incidence of Childhood ALL in Malaysia	10
2.2 Chemotherapy and Management of Childhood ALL	14
2.2.1 Major Clinical Trials for Children with ALL	14
2.2.2 Methotrexate (MTX) Chemotherapy in ALL Protocol	15
2.2.3 The Mechanism of Action and Metabolism of MTX	16
2.2.4 Therapeutic Drug Monitoring of High Dose MTX	18
2.3 Pharmacogenomics in Childhood ALL	18
2.4 Application of Metabolomics Towards Treatment for ALL.	23